3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
154
Stomach Neoplasms
23
Neoplasms
18
Neoplasm Metastasis
17
Esophageal Neoplasms
16
Esophageal Squamous Cell Carcinoma
12
Cholangiocarcinoma
12
Adenocarcinoma
11
Breast Neoplasms
9
Pancreatic Adenocarcinoma
8
Colorectal Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Ovarian Neoplasms
7
Carcinoma, Pancreatic Ductal
7
Biliary Tract Neoplasms
7
Lung Neoplasms
6
Gallbladder Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Pancreatic Diseases
5
Digestive System Neoplasms
5
Urinary Bladder Neoplasms
4
Triple Negative Breast Neoplasms
4
Sarcoma
4
Prostatic Neoplasms
4
Endocrine Gland Neoplasms
4
Digestive System Diseases
4
Advanced Pancreatic Cancer
4
Rectal Neoplasms
3
Neoplasms, Glandular and Epithelial
3
Neoplasms by Site
3
Interventions
trifluridine tipiracil drug combination
1
reolysin
1
atezolizumab
1
Gemcitabine
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anal Cancer Metastatic
×
Albumin-Bound Paclitaxel
×
Gastrointestinal
×
Clear all
NCT07280377
2026-05-19
GOBLET
Oncolytics Biotech
Phase 1/2
Active not recruiting
122 enrolled